Latest news with #plaque psoriasis
Yahoo
11-07-2025
- Business
- Yahoo
VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress
VYNE Therapeutics Inc. (NASDAQ:VYNE) is among the . Analysts at H.C. Wainwright have reaffirmed their Buy rating on VYNE Therapeutics Inc. (NASDAQ:VYNE), with a price target of $4.50, implying an upside of nearly 215%. This optimism follows the company's advancement of its VYN202 program for moderate-to-severe plaque psoriasis. Just recently, the company's Phase 1b trial was put on hold by the FDA due to testicular toxicity outcomes in dogs during non-clinical studies. The study, however, has been permitted to proceed in female patients at the 0.25 mg and 0.5 mg dosing levels. Since a higher 1 mg dose was excluded because of its narrower safety margin, VYNE Therapeutics Inc. (NASDAQ:VYNE) must first complete a 12-week non-clinical toxicology study in dogs before resuming male enrollment. A close-up shot of a male patient in a clinical trial, receiving the latest therapeutic treatment with a BET inhibitor. What provides the company financial stability at this crucial development stage is its high current ratio and low debt. After the study's status update, VYNE Therapeutics Inc. (NASDAQ:VYNE) unblinded data from the enrolled participants, showing no serious side effects and no treatment discontinuations associated with the adverse cases. VYNE Therapeutics Inc. (NASDAQ:VYNE), based in New Jersey, is a clinical-stage biopharmaceutical company that engages in the development of therapies to address chronic inflammatory and immune-mediated conditions. Founded in 2020, the company is committed to improving the immune system and inflammation. While we acknowledge the potential of VYNE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Medscape
11-07-2025
- Health
- Medscape
Fast Five Quiz: Plaque Psoriasis
Psoriasis manifests as plaque psoriasis in 80%-90% of cases. Additionally, these patients can be affected by multiple comorbidities, including psoriatic arthritis, depression, obesity, diabetes, liver disease, and metabolic syndrome. Approximately 125 million people around the world have this condition, making it a considerable public health challenge. How much do you know about plaque psoriasis? Test your knowledge with this quick quiz. The prevalence of plaque psoriasis between adult males and females has been shown to be generally similar, but females tend to have an earlier age of onset. Genetic factors are believed to play a role in the pathophysiology of psoriasis. For example, human leukocyte antigen (HLA)-B13, HLA-B17, and HLA-Cw6 are associated with plaque psoriasis, and family history has been identified as a predictor of disease occurrence. Though plaque psoriasis can develop at any age, several peak age ranges for the onset of plaque psoriasis have been identified (mainly ages 15-22 years and 55-70 years). Learn more about the epidemiology of plaque psoriasis. Many environmental factors have been linked to psoriasis and plaque psoriasis. Specifically, cigarette smoking conveys an increased risk for the development of plaque psoriasis. Other environmental factors that increase the risk of developing plaque psoriasis include all types of trauma, such as physical, chemical, electrical, surgical, infective, and inflammatory injury. Further, low humidity has also been identified as a possible trigger. Learn more about the etiology of plaque psoriasis. Latest guidelines from the American Academy of Dermatology and National Psoriasis Foundation recommend earlier and more frequent screening for hypertension, diabetes, and hyperlipidemia in patients with ≥ 10% of their body surface area affected by psoriasis. These comorbidities have long been linked to psoriasis. Additionally, shared genetic pathways have been found between psoriasis and cardiometabolic diseases, including hyperlipidemia. Learn more about comorbidities of plaque psoriasis. Histologic findings in patients with plaque psoriasis include abnormal differentiation and excessive proliferation of keratinocytes, which is manifested by the loss of the granular layer. The diagnosis of plaque psoriasis is usually made based on clinical findings. A skin biopsy can confirm a diagnosis of plaque psoriasis, but it is usually not required. Biopsies are typically reserved for the evaluation of atypical cases or to rule out other conditions when there is diagnostic uncertainty. Similarly, laboratory investigations are rarely required for diagnosis or workup. Patients with severe disease might have mild hyperuricemia and low folate levels, which are believed to result from enhanced epidermopoiesis. Signs of inflammation can be seen throughout the dermis in persons with plaque psoriasis, including marked hypervascularity and an increase in the size of the dermal papillae. Learn more about the signs and symptoms of plaque psoriasis. Like other systemic agents, biologic therapies can be considered for patients with moderate-to-severe and refractory plaque psoriasis. They can be used initially in this setting as well. For mild-to-moderate plaque psoriasis, topical corticosteroids are usually the initial treatment. Further, combination topical/systemic therapy appears to yield better outcomes than either treatment used alone for the treatment of plaque psoriasis. Not every patient with plaque psoriasis requires phototherapy; it is usually used in patients with extensive, widespread disease (ie, more lesions than can easily be counted) and in conjunction with other treatments. Patients who are resistant to topical treatment may also be candidates for phototherapy. Learn more about treatment options for plaque psoriasis.
Medscape
11-07-2025
- Health
- Medscape
Fast Five Quiz: Presentation and Diagnosis Plaque Psoriasis
Plaque psoriasis is the most common form of psoriasis. Recognition of symptoms and prompt diagnosis are critical to prevent the progression of joint damage and to improve patients' quality of life and long-term physical function. How much do you know about the presentation and diagnosis of plaque psoriasis? Test your knowledge with this quick quiz. According to a recent analysis, patients with moderate disease most commonly present with more cracked skin, tender skin, and redness or discoloration than those with mild disease at diagnosis. Conversely, scaling and flaking are less common in patients with moderate psoriasis at diagnosis than in those with mild disease. Although both mild and moderate psoriasis can present with other symptoms such as pruritus, burning, and pain/stiffness in joints, the differences in prevalence are not statistically significant or as distinctive. Learn more about physical examination for plaque psoriasis. Guttate psoriasis is normally self-limited, but in some cases, it can progress to chronic plaque psoriasis. Patients with plaque psoriasis have frequently reported worsening of symptoms in the winter and improvement of symptoms with warmer weather; however, symptoms can worsen at any time, depending on the patient. Koebner phenomenon refers to the appearance of new lesions at sites of injury or trauma to the skin. It is believed to occur in up to 75% of patients with psoriasis. Pruritus is a cardinal feature of plaque psoriasis and can occur with any severity of disease. Learn more about the presentation of plaque psoriasis. The physical examination of a patient with plaque psoriasis might reveal symmetrical lesions on the scalp, trunk, buttocks, and limbs as well as the extensor surfaces of the knees, elbows, and genitals. In some cases, plaque psoriasis might present as well-demarcated oval-shaped plaques that can range in size. Widespread erythema covering nearly the entire body with variable amounts of scaling is more likely to be seen with erythrodermic psoriasis, not plaque psoriasis; it is considered a life-threatening emergency, as these patients are at risk for hemodynamic instability. Drop-shaped, salmon-colored papules with fine scale are more characteristic of guttate psoriasis, not plaque psoriasis. Learn more about the signs and symptoms of plaque psoriasis. Psoriatic plaques tend to have a high degree of uniformity with few morphologic differences between the two sides. Fissuring within psoriatic plaques can occur when lesions are present over joint lines or on the palms and soles. They are raised and easily palpable owing to the thickened epidermis, expanded dermal vascular compartment, and infiltrate of neutrophils and lymphocytes that are characteristic of the disease. Further, psoriatic plaques are symmetrically distributed over the body. Learn more about the signs and symptoms of plaque psoriasis. According to a review consisting of patient data, Black individuals with psoriasis reported lower amounts of erythema but higher rates of dyspigmentation and more BSA involvement than White individuals. Moreover, other data have indicated that lasting skin dyspigmentation is also among the most frequent complaints in patients with skin of color, and Black individuals might have thicker plaques that appear grayish or purple. Additionally, scalp psoriasis is more commonly seen in Asian and Black individuals than in Western European individuals, and Asian and Hispanic individuals are also more likely to cite stress as an exacerbating factor than White individuals. Learn more about the nuances of plaque psoriasis presentation.
